UCSF

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

Retrieved on: 
星期三, 四月 17, 2024
Research, Infectious Diseases, Neurology, Biotechnology, Other Health, Health, General Health, Other Science, Science, American Academy, GenePeeks, University, Cancer, Foundation Medicine, Genomics, DSM-IV codes, Infection, Bacteria, Fortune 500, Medical laboratory, Clear Labs, NGS, CLIA, Medicine, Encephalitis, UCSF, Ventricular septal defect, Patient, Meningitis, Parasitism, AAN, Physician, Immunodeficiency, Virus, Neuro, Fungus, CSF, Diagnosis, Neoplasm, Cerebrospinal fluid, Metagenomics, Pharmaceutical industry

The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.

Key Points: 
  • The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.
  • In addition, the study found mNGS provided a definitive diagnosis for nearly 1 in 3 immunocompromised patients.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.
  • Prior to joining Delve Bio, Mr. Field served as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina).

AMPEL BioSolutions Selected as Member of ARPA-H Customer Experience Hub Spoke Network

Retrieved on: 
星期二, 四月 23, 2024
Mayo Clinic, DARPA, Providence Healthcare, Inflammation, United, Lupus, Capital, Blood, ARPANET, Partnering, Health, Cleveland Clinic, MUSC, Customer experience, Nation, University, Autoimmunity, Disease, Duke, UCSF, ARPA, Gene expression, QuidelOrtho, Mass General Brigham, Clinical trial, Medicine, Biotechnology

CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .

Key Points: 
  • CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .
  • AMPEL's ARPA-H spoke election highlights one-of-a-kind Precision Health tests that predict inflammation and abnormal drug targets from gene expression utilizing "explainable AI" (xAI).
  • Other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs.
  • As a Customer Experience spoke, AMPEL has access to funding and flexible contracting for expeditious product execution and scaling.

Renowned Alzheimer's Neurologist Dale Bredesen, MD, Joins Pacific Neuroscience Institute

Retrieved on: 
星期二, 四月 16, 2024
UCLA, Neurodegenerative disease, Alzheimer's disease, Duke University Hospital, Brain, University, Dementia, Recode, Hope, NIH, Risk, Arrest, University of California, PNI, Doctor of Philosophy, The New York Times, Research, Trial of the century, History, Confusion, Exercise, Documentation, Ageing, UCSF, Buck, Patient, Survivor, Neurology, Medicine, Faculty, Amnesia, Quality of life, Nobel, UC, Nursing

SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®. Over the past four months, as the senior director of the nascent Precision Brain Health program, he and his colleagues have been intensely focused on developing what promises to be the world's first formalized system to comprehensively address neurodegenerative disease in the world. While not quite ready for primetime, the excitement around the clinical implications for patients is palpable.

Key Points: 
  • SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®.
  • Taking a personalized, biological systemwide approach and becoming proactive about interventions, represent the first steps towards stopping Alzheimer's in its tracks."
  • Pacific Neuroscience Institute has a history of innovation that fits perfectly with the development of this novel program."
  • He directed the Program on Aging at the Burnham Institute and joined the Buck Institute as founding president and CEO.

Canopy Health and UCSF Health Announce Deep Collaboration on Bay Area Access and Affordability

Retrieved on: 
星期二, 四月 16, 2024
Dignity, Hospital, Health, Thought, HMO, UCSF Medical Center, Nursing, UCSF, Patient, MPH, Physician, Wood, Home

EMERYVILLE, Calif., April 16, 2024 /PRNewswire/ -- Canopy Health and UCSF Health are excited to announce a strategic collaboration that will leverage UCSF's deep population health and data analytic expertise to drive best-in-class care delivery for Canopy Health's 40,000 HMO members.

Key Points: 
  • EMERYVILLE, Calif., April 16, 2024 /PRNewswire/ -- Canopy Health and UCSF Health are excited to announce a strategic collaboration that will leverage UCSF's deep population health and data analytic expertise to drive best-in-class care delivery for Canopy Health's 40,000 HMO members.
  • "Canopy Health welcomes this strong collaboration with the world-class experts at UCSF," stated Ken Wood, Canopy Health's CEO.
  • A second area of focus for Dr. Judson's work will support improving access to needed medical care for new patients who join Canopy Health.
  • Canopy Health's patients range from newborns to centenarians – all deserving of tailored care and appropriate access.

Hyalex Orthopaedics Appoints Thomas Vail, M.D., as Chief Medical Officer and Names Adam Gridley to Board of Directors

Retrieved on: 
星期一, 四月 15, 2024
Education, Sale, University, Hip, Regenerative medicine, Abstract, Merz Pharma, Cartilage, Research, Trustee, ARM, Orthopedic surgery, IPO, Journal, Therapy, UCSF, Joint, Patient, Health, Biotechnology, Global health, Pharmaceutical industry

LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer. Dr. Vail is internationally recognized as a specialist in total and partial joint replacement and surgical treatment of hip and knee conditions, having most recently served as the Michael and Antoinette Pappas endowed chair and James L. Young professor of orthopaedic surgery at the University of California, San Francisco (UCSF). Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors. These two appointments significantly augment the scientific and operational expertise of the Hyalex team at a time when the company is bringing its novel HYALEX Cartilage platform into first-in-human clinical trials.

Key Points: 
  • LEXINGTON, Mich., April 15, 2024 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer.
  • Additionally, Hyalex announced the appointment of Adam Gridley, the chief executive officer of Allay Therapeutics, to the company's board of directors.
  • "Hyalex is entering an exciting and transformational period for the company, as we advance our novel HYALEX Cartilage platform into the clinic for the first time.
  • "We look forward to the important contributions that both Tad and Adam will make to the success of the company."

Top 10 Best Practices for Website Accessibility Design and Development from a Leading Design Agency in the SF Bay Area

Retrieved on: 
星期三, 四月 10, 2024
Education, Paratriathlon, Mac, ARIA, Smash, Disability, EMS, Semantics, Accessibility, Adobe, Conference, UC, WordPress, HTML, Stanford University, UCSF, Eye, XD, Rems, University of California, Berkeley, Multimedia, AA, Government, WCAG, Online shopping

BERKELEY, Calif., April 10, 2024 /PRNewswire-PRWeb/ -- Have you ever turned on the speech reader on your Mac and closed your eyes while navigating a website? It's a powerful test to learn how visually impaired people might experience your content.

Key Points: 
  • With the evolving landscape of digital content, it's essential for us as designers to stay up-to-date with the latest accessibility standards and best practices.
  • Many of these guidelines are considered best practices in website design and development; a few, however, are easy to overlook.
  • Alt text is an essential part of website accessibility, as it describes the content of images to visually impaired users.
  • Some of us from P6 enjoyed the Smashing SF Conference which had several sessions on accessibility, front-end design, boosting web performance, and more.

NBME Recognizes Dr. Karen Hauer with Prestigious Medical Education Research Award

Retrieved on: 
星期二, 四月 2, 2024
Medical education, Internal medicine, Education, UCSF, Communication, Learning, Science, International, Patient, Bias, Knowledge, Research, University, Doctor of Philosophy, Faculty, MD, Student, Thought, MBA, UCSF Medical Center, Habit, Stanford University, Feedback, Physician, Health, NBME, Nursing

PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Karen Hauer, MD, PhD, was selected as the recipient of NBME’s 2024 John P. Hubbard Award in recognition of her significant contributions to the field of medical education research and assessment.

Key Points: 
  • PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Karen Hauer, MD, PhD, was selected as the recipient of NBME’s 2024 John P. Hubbard Award in recognition of her significant contributions to the field of medical education research and assessment.
  • NBME President and CEO Peter Katsufrakis, MD, MBA, echoes her sentiments about past Hubbard Award recipients and expresses his support and admiration for Dr. Hauer and her accomplishments.
  • She is an active researcher in health professions education with a focus on competency-based medical education, workplace-based assessment, equity and coaching.
  • P. Hubbard Award recognizes individuals for their outstanding contributions to the pursuit of assessment excellence within medical education.

American Shared Hospital Services Pays Tribute to Ernest A. Bates, M.D., Founder and Former Chairman and CEO

Retrieved on: 
星期二, 三月 26, 2024
MRI, Radiosurgery, UCSF, Jacobi Medical Center, ASHS, Executive, Trustee, SAN, Black, University, MD, Medical Center, Dentistry, University of California, Johns Hopkins University, AMS, M.D

Ray Stachowiak, Executive Chairman of American Shared Hospital Services, remembers Dr. Bates fondly, stating, “We want to thank him for his profound contributions to the Company and to many people, including me, personally, for the past 35 years.

Key Points: 
  • Ray Stachowiak, Executive Chairman of American Shared Hospital Services, remembers Dr. Bates fondly, stating, “We want to thank him for his profound contributions to the Company and to many people, including me, personally, for the past 35 years.
  • He expanded accessibility to centers throughout the U.S. and in South America, building a solid foundation for American Shared Hospital Services’ future success.
  • Known for his intellectual curiosity, generous philanthropy, and longstanding service and dedication to American Shared Hospital Services, Dr. Bates was widely known in the healthcare industry and forged long-term friendships throughout his lifetime.
  • He previously provided consulting services to the Company pursuant to a consulting agreement from December 2021 through March 2022 before rejoining the Board in March 2022.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
星期二, 三月 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
星期二, 四月 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Tobacco, Clinical Trials, Retail, Disease, Cardiovascular Research, Society, IND, Psychology, Therapy, Senior counsel, Population health, School, Dean (education), Partnership, Nicotine, Policy, Smoker, Behavior, NIH, Brown University, Trial of the century, University, SAB, Pharmacology, Homelessness, San Francisco General Hospital, UCSF, Public, Cancer, MD, Publication, Heated tobacco product, Hospital, Juul, FDA, Alpert Medical School, Pregnancy, Chair, Public health, University of Kansas, Cardiology, CTA, Mortality, Louisiana State University, Doctor of Philosophy, MHRA, Smoking, Toxicology, Division, Brown, Social science, Pharmaceutical industry

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.